Realcan Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 4/6
Realcan Pharmaceutical Group has a total shareholder equity of CN¥5.7B and total debt of CN¥6.6B, which brings its debt-to-equity ratio to 115.5%. Its total assets and total liabilities are CN¥16.0B and CN¥10.3B respectively. Realcan Pharmaceutical Group's EBIT is CN¥76.2M making its interest coverage ratio -0.8. It has cash and short-term investments of CN¥5.0B.
Key information
115.5%
Debt to equity ratio
CN¥6.57b
Debt
| Interest coverage ratio | -0.8x |
| Cash | CN¥4.98b |
| Equity | CN¥5.69b |
| Total liabilities | CN¥10.32b |
| Total assets | CN¥16.01b |
Recent financial health updates
Recent updates
We Think Realcan Pharmaceutical Group (SZSE:002589) Has A Fair Chunk Of Debt
Dec 12
Realcan Pharmaceutical Group (SZSE:002589) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 06Improved Revenues Required Before Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Stock's 36% Jump Looks Justified
Oct 18Realcan Pharmaceutical Group's (SZSE:002589) Earnings Seem To Be Promising
May 06Financial Position Analysis
Short Term Liabilities: 002589's short term assets (CN¥11.1B) exceed its short term liabilities (CN¥9.9B).
Long Term Liabilities: 002589's short term assets (CN¥11.1B) exceed its long term liabilities (CN¥384.4M).
Debt to Equity History and Analysis
Debt Level: 002589's net debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: 002589's debt to equity ratio has increased from 64.1% to 115.5% over the past 5 years.
Debt Coverage: 002589's debt is not well covered by operating cash flow (2.4%).
Interest Coverage: 002589 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 08:49 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Realcan Pharmaceutical Group Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Xu Qing Liu | Chasing Securities |